IQVIA Holdings (IQV) executive Fedock received 18,634 Stock Appreciation Right
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Michael J. Fedock (executive at IQVIA Holdings Inc., IQV) reported that they received 18,634 Stock Appreciation Right on Feb 9, 2026.
- Reporting person
- Fedock Michael J.
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Grant or award (A) | Stock Appreciation RightOn 18,634 Common Stock1 | +18,634 | - | - | 18,634 direct |
Holdings before and after
- Stock Appreciation Right: 0 to 18,634 direct
Footnotes from the filing
- 1. This stock appreciation right vests in three annual installments beginning on February 9, 2027.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Fedock report in this IQV Form 4?
Michael J. Fedock (executive at IQVIA Holdings Inc., IQV) reported that they received 18,634 Stock Appreciation Right on Feb 9, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for IQV
Across the 12 sessions after earlier IQV headlines, the stock closed higher 3 times and lower 9 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IQV | SPY |
|---|---|---|---|
| Feb 10, 2026 | IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions | -5.3% | -0.3% |
| Feb 5, 2026 | IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance | -10.7% | -1.2% |
| Jan 29, 2026 | IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration | -1.7% | -0.2% |
| Jan 23, 2026 | IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year | -1.6% | +0.0% |
| Jan 21, 2026 | IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026 | +3.3% | +1.2% |
| Dec 2, 2025 | Morgan Stanley resumed coverage on IQVIA with a new price targetand 1 other headline that session | -1.2% | +0.2% |
Earlier insider filings at IQV
- Feb 11, 2026SEC Form 4 filed by Officer Cherofsky Keriann
- Feb 11, 2026SEC Form 4 filed by Officer Berkshire James G.
- Feb 11, 2026SEC Form 4 filed by Officer Bousbib Ari
- Feb 11, 2026SEC Form 4 filed by Director Wims Morris Leslie
- Feb 11, 2026SEC Form 4 filed by Director Goggins Colleen A
Quantisnow market dataNYSE
IQV
IQVIA Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Listed since
- 2013
Get push alerts for IQV
Full IQV profile on Quantisnow Follow IQV and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time